LB Pharmaceuticals Inc Common Stock (LBRX) — Financial statements
Income statement, balance sheet, and cash flow for LB Pharmaceuticals Inc Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | |||||
| R&D Expenses | 17↓67.3% | 51↑552.3% | 8↑482.8% | 1 | |
| General & Administrative Expenses | 14↑0.0% | 14↑286.8% | 4↑141.4% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 14↑0.0% | 14↑286.8% | 4↑141.4% | 1 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 30↓53.1% | 65↑469.9% | 11↑305.0% | 3 | |
| Total Costs & Expenses | 30↓53.1% | 65↑469.9% | 11↑305.0% | 3 | |
| Operating Results | |||||
| Operating Income | -30↑53.1% | -65↓469.9% | -11↓305.0% | -3 | |
| Depreciation & Amortization | 0.32↑252.7% | 0.09↑2175.0% | 0.00↑100.0% | 0.00 | |
| EBITDA | -30↑52.3% | -63↓4260.6% | -1↑88.1% | -12 | |
| EBIT | -30↑51.8% | -63↓4254.8% | -1↑88.1% | -12 | |
| Interest & Other Income | |||||
| Net Interest Income | 4↑127.8% | 2↑142.9% | -4↓93.2% | -2 | |
| Interest Income | 4↑127.8% | 2↑112.2% | 0.81↑1011.0% | 0.07 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 5↑124.3% | 2 | |
| Non-Operating Income | 0.00↑100.0% | -2↑82.6% | -10↓205.8% | 9 | |
| Other Income / Expenses | 5↑200.8% | 2↓66.1% | 5↑144.2% | -12 | |
| Income Before Tax | -25↑60.1% | -63↓905.8% | -6↑56.3% | -14 | |
| Income Tax Expense | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | -25↑60.1% | -63↓905.6% | -6↑56.3% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -25↑60.1% | -63↓905.6% | -6↑56.3% | -14 | |
| Bottom-Line Net Income | -25↑60.1% | -63↓905.6% | -6↑56.3% | -14 | |
| EPS (Basic) | -1.00↑94.4% | -17.83↓907.3% | -1.77↑56.3% | -4.05 | |
| EPS (Diluted) | -1.00↑94.4% | -17.83↓907.3% | -1.77↑56.3% | -4.05 | |
| Weighted Average Shares | 25↑614.8% | 4↓0.0% | 4↑0.0% | 4 | |
| Weighted Average Diluted Shares | 25↑614.8% | 4↓0.0% | 4↑0.0% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.